title: Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum.
abstract: An AIDS patient with disseminated histoplasmosis who improved during treatment with fluconazole but remained fungemic and subsequently relapsed is described. Isolates obtained from blood during therapy showed a progressive increase in fluconazole MIC from 0.625 to 20 micrograms/ml. The pretreatment, or parent, isolate and the posttreatment, or relapse, isolate demonstrated identical genetic patterns by PCR fingerprinting with three different primers. Fluconazole was less potent inhibitor of the growth of the relapse isolate than of the pretreatment isolate (50% inhibitory concentration [IC50] = 11.7 microM), while itraconazole was more potent (relapse isolate IC50 = 0.0011 microM versus pretreatment isolate IC50 = 0.0064 microM). Neither the increased sensitivity to itraconazole nor the decreased activity of fluconazole on the growth of the relapse isolate results from changes in the intracellular content of these agents. To reach 50% inhibition of ergosterol synthesis in both the parent and relapse isolates, about 2 nM itraconazole was needed; with fluconazole, 50% inhibition was achieved at 20.9 microM and 55.5 microM, respectively. Resistance to fluconazole may develop during treatment and results from decreased sensitivity of ergosterol synthesis.
authors.affiliation: Department of Medicine and Pathology, Indiana University School of Medicine, Indianapolis, USA. joe@idwish.dmed.iupui.edu
authors.forename: J
authors.initials: J
authors.lastname: Wheat
authors.forename: P
authors.initials: P
authors.lastname: Marichal
authors.forename: H
authors.initials: H
authors.lastname: Vanden Bossche
authors.forename: A
authors.initials: A
authors.lastname: Le Monte
authors.forename: P
authors.initials: P
authors.lastname: Connolly
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy*; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004875:Ergosterol / Q000096:biosynthesis; D015725:Fluconazole / Q000627:therapeutic use*; D006658:Histoplasma / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006660:Histoplasmosis / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D015725:Fluconazole; D004875:Ergosterol